Pharmaceutical composition for treating chronic stable angina pectoris with hyperlipemia

A technology for stable angina pectoris and hyperlipidemia, applied in the direction of drug combinations, non-active ingredients of polymer compounds, active ingredients of heterocyclic compounds, etc., can solve the problems of angina pectoris, the potential danger of ineffective suppression of angina pectoris, and the treatment of angina pectoris, etc. Achieve the effects of increasing intake and catabolism, good hemorheology effect, and good blood lipid-lowering effect

Active Publication Date: 2009-10-21
CSPC OUYI PHARM CO LTD
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, there is no medicine dedicated to the treatment of stable angina associated with hyperlipidemia in clinical practice. Although the above-mentioned 5 drug regimens can effectively relieve the symptoms of angina pectoris, since hyperlipidemia can cause coronary arterioscler

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating chronic stable angina pectoris with hyperlipemia
  • Pharmaceutical composition for treating chronic stable angina pectoris with hyperlipemia
  • Pharmaceutical composition for treating chronic stable angina pectoris with hyperlipemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1～5

[0034] One, embodiment 1~5: tablet composition

[0035] Component Example 1 2 3 4 5

[0036] Ivabradine hydrochloride 2.5 10 5 7.5 5

[0037] Atorvastatin Calcium 10 50 75 2.5 100

[0038]β-Cyclodextrin 10 30 40 20 50

[0039] Water 40 60 80 40 100

[0040] Microcrystalline cellulose 10 20 25 20 40

[0041] Compressible starch 20 40 20 30 40

[0042] Magnesium stearate 1 1 1 1 1

[0043] The above formula is the content of 1000 tablets, and the unit is gram.

[0044] Preparation method: Grind ivabradine hydrochloride, atorvastatin calcium, 3-cyclodextrin and water at high speed for 1 hour, then dry in vacuum at 40°C, pulverize, pass through a 100-mesh sieve, add the remaining materials, and mix in a mixer for 10 Minutes, tableting, packaging after passing the test.

Embodiment 6～10

[0045] Two, embodiment 6~10: capsule composition

[0046] Component Example 6 7 8 9 10

[0047] Ivabradine hydrochloride 2.5 10 5 7.5 5

[0048] Rosuvastatin Calcium 5 2.5 100 20 75

[0049] β-Cyclodextrin 20 30 50 40 35

[0050] water 40 10 30 20 40

[0051] Starch 240 200 250 220 230

[0052] Magnesium stearate 2 6 10 8 4

[0053] The above-mentioned formula is the content of 1000 grains, and the unit is gram.

[0054] Preparation method: Grind ivabradine hydrochloride, rosuvastatin calcium, β-cyclodextrin and water at high speed for 1 hour, then dry in vacuum at 40°C, pulverize, pass through a 100-mesh sieve, add the remaining raw materials, and mix in a mixer for 10 Minutes, filling capsules, packaging after passing the test.

[0055] 3. Clinical trial of combination of atorvastatin calcium and ivabre hydrochloride in the treatment of stable angina pectoris complicated with hyperlipidemia

[0056] 1 Materials and methods

[0057] 1.1 The clinical data and diagnosi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a pharmaceutical composition for treating chronic stable angina pectoris with hyperlipermia, which comprises the components of a drug carrier, a sino atrial node If current selective specificity inhibitor or pharmaceutical salt thereof, and an HMG-CoA reductase selective depressant or pharmaceutical salt thereof; the sino atrial node If current selective specificity inhibitor or the pharmaceutical salt thereof is Ivabradine hydrochloride; and the contents of the components of the medical composition by mass unit are 2.5 to 10 of the sino atrial node If current selective specificity inhibitor and 2.5 to 100 of the HMG-CoA reductase selective depressant. The medical composition has good synergistic effect when treating the chronic stable angina pectoris with the hyperlipermia, and has good effect of lowering hyperlipemia for hyperlipoidemia and hemorheology effect.

Description

technical field [0001] The invention relates to a composition with medicinal activity, in particular to a pharmaceutical composition for treating hyperlipidemia complicated with chronic stable angina pectoris, which belongs to the technical field of medicine. Background technique [0002] Angina pectoris (angina pectoris) is a clinical syndrome caused by coronary insufficiency, myocardial acute, temporary ischemia and hypoxia, which is characterized by paroxysmal chest squeezing pain sensation. Stable angina pectoris (stable angina pectoris), that is, stable exertional angina pectoris, is the most common angina pectoris. The degree, frequency, nature and triggering factors of this type of angina pectoris do not change significantly within 1 to 3 months. [0003] The most common cause of chronic stable angina is fixed coronary artery stenosis accompanied by increased myocardial oxygen consumption. Coronary atherosclerosis mainly affects the blood supply of the myocardium. Whe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61K31/55A61K47/40A61P3/06A61P9/10A61K31/40
Inventor 李国聪郭卫芹张育高志峰胡艳茹马岩
Owner CSPC OUYI PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap